000169932 001__ 169932
000169932 005__ 20240229133700.0
000169932 020__ $$a978-3-030-62657-0 (print)
000169932 020__ $$a978-3-030-62658-7 (electronic)
000169932 0247_ $$2doi$$a10.1007/978-3-030-62658-7_1
000169932 0247_ $$2pmid$$apmid:34286437
000169932 0247_ $$2ISSN$$a0065-2598
000169932 0247_ $$2ISSN$$a2214-8019
000169932 0247_ $$2doi$$adoi: 10.1007/978-3-030-62658-7_1
000169932 037__ $$aDKFZ-2021-01638
000169932 041__ $$aEnglish
000169932 082__ $$a570
000169932 1001_ $$0P:(DE-He78)38011b297ae5243d14aade852e9bf4d9$$aO'Connor, Tracy Lynn$$b0$$eFirst author$$udkfz
000169932 245__ $$aCCL2 in the Tumor Microenvironment.
000169932 260__ $$a[Heidelberg]$$bSpringer$$c2021
000169932 3367_ $$2DRIVER$$aarticle
000169932 3367_ $$2DataCite$$aOutput Types/Journal article
000169932 3367_ $$0PUB:(DE-HGF)3$$2PUB:(DE-HGF)$$aBook$$mbook
000169932 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1627464227_7922
000169932 3367_ $$2BibTeX$$aARTICLE
000169932 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169932 3367_ $$00$$2EndNote$$aJournal Article
000169932 500__ $$a#EA:F180#LA:F180#
000169932 520__ $$aThe C-C motif chemokine ligand 2 (CCL2) is a crucial mediator of immune cell recruitment during microbial infections and tissue damage. CCL2 is also frequently overexpressed in cancer cells and other cells in the tumor microenvironment, and a large body of evidence indicates that high CCL2 levels are associated with more aggressive malignancies, a higher probability of metastasis, and poorer outcomes in a wide range of cancers. CCL2 plays a role in recruiting tumor-associated macrophages (TAMs), which adopt a pro-tumorigenic phenotype and support cancer cell survival, facilitate tumor cell invasion, and promote angiogenesis. CCL2 also has direct, TAM-independent effects on tumor cells and the tumor microenvironment, including recruitment of other myeloid subsets and non-myeloid cells, maintaining an immunosuppressive environment, stimulating tumor cell growth and motility, and promoting angiogenesis. CCL2 also plays important roles in the metastatic cascade, such as creating a pre-metastatic niche in distant organs and promoting tumor cell extravasation across endothelia. Due to its many roles in tumorigenesis and metastatic processes, the CCL2-CCR2 signaling axis is currently being pursued as a potential therapeutic target for cancer.
000169932 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000169932 588__ $$aDataset connected to CrossRef Book Series, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169932 650_7 $$2Other$$aAngiogenesis
000169932 650_7 $$2Other$$aCCL2
000169932 650_7 $$2Other$$aCCR2
000169932 650_7 $$2Other$$aCancer
000169932 650_7 $$2Other$$aExtravasation
000169932 650_7 $$2Other$$aImmunity
000169932 650_7 $$2Other$$aImmunosuppression
000169932 650_7 $$2Other$$aInvasion
000169932 650_7 $$2Other$$aMCP-1
000169932 650_7 $$2Other$$aMacrophage
000169932 650_7 $$2Other$$aMetastasis
000169932 650_7 $$2Other$$aMicroenvironment
000169932 650_7 $$2Other$$aNFκB
000169932 650_7 $$2Other$$aTAM
000169932 650_7 $$2Other$$aTumor
000169932 650_7 $$2NLM Chemicals$$aChemokine CCL2
000169932 650_7 $$2NLM Chemicals$$aChemokines
000169932 650_7 $$2NLM Chemicals$$aLigands
000169932 650_7 $$2NLM Chemicals$$aReceptors, CCR2
000169932 650_2 $$2MeSH$$aCell Line, Tumor
000169932 650_2 $$2MeSH$$aChemokine CCL2: genetics
000169932 650_2 $$2MeSH$$aChemokines
000169932 650_2 $$2MeSH$$aLigands
000169932 650_2 $$2MeSH$$aReceptors, CCR2: genetics
000169932 650_2 $$2MeSH$$aTumor Microenvironment
000169932 7001_ $$0P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aHeikenwälder, Mathias$$b1$$eLast author$$udkfz
000169932 773__ $$0PERI:(DE-600)2385266-5$$a10.1007/978-3-030-62658-7_1$$p1-14$$tAdvances in experimental medicine and biology$$v1302$$x0065-2598$$y2021
000169932 909CO $$ooai:inrepo02.dkfz.de:169932$$pVDB
000169932 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)38011b297ae5243d14aade852e9bf4d9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169932 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169932 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000169932 9130_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000169932 9141_ $$y2021
000169932 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bADV EXP MED BIOL : 2019$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000169932 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-28
000169932 9201_ $$0I:(DE-He78)F180-20160331$$kF180$$lF180 Chronische Entzündung und Krebs$$x0
000169932 980__ $$ajournal
000169932 980__ $$aVDB
000169932 980__ $$abook
000169932 980__ $$aI:(DE-He78)F180-20160331
000169932 980__ $$aUNRESTRICTED